Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages

被引：23

作者：

Banerjea A. ^{[1
]}

Li M.-J. ^{[2
]}

Remling L. ^{[1
]}

Rossi J. ^{[2
]}

Akkina R. ^{[1
]}

机构：

[1] Dept. Microbiology, Immunology and Pathology, Colorado State University, Fort Collins

[2] Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010

来源：

AIDS Research and Therapy | / 1卷 / 1期

关键词：

AIDS gene therapy; HIV tar decoy; CCR5 ribozyme; SCID-hu mice; Lentiviral vectors; HIV aptamers; CD34 cells;

D O I：

10.1186/1742-6405-1-2

中图分类号：

学科分类号：

摘要：

Background: RNA based antiviral approaches against HIV-I are among the most promising for long-term gene therapy. These include ribozymes, aptamers (decoys), and small interfering RNAs (siRNAs). Lentiviral vectors are ideal for transduction of such inhibitory RNAs into hematopoietic stem cells due to their ability to transduce non-dividing cells and their relative refractiveness to gene silencing. The objective of this study is to introduce an HIV-I Tar aptamer either alone or in combination with an anti-CCR5 ribozyme into CD34+ hematopoietic progenitor cells via an HIV-based lentiviral vector to derive viral resistant progeny T cells and macrophages. Results: High efficiency and sustained gene transfer into CD34+ cells were achieved with lentiviral vector constructs harboring either Tar decoy or Tar decoy in combination with CCR5 ribozyme. Cells transduced with these constructs differentiated normally into T-lymphocytes in vivo in thy/liv grafts of SCID-hu mice, and into macrophages in vitro in the presence of appropriate growth factors. When challenged in vitro, the differentiated T lymphocytes and macrophages showed marked resistance against HIV-I infection. Conclusions: Viral resistant transgenic T cells and macrophages that express HIV-I Tar aptamer either alone or in combination with an anti-CCR5 ribozyme could be obtained by lentiviral gene transduction of CD34+ progenitor cells. These results showed for the first time that expression of these anti-HIV-I transgenes in combination do not interfere with normal thymopoiesis and thus have set the stage for their application in stem cell based gene therapy for HIV/AIDS. © 2004 Banerjea et al; licensee BioMed Central Ltd.

引用

共 26 条

[1] Stevenson M., HIV-I Pathogenesis, Nat Med, 9, pp. 853-860, (2003)
[2] Berger E.A., Murphy P.M., Farber J.M., Chemokine receptors as HIV-I coreceptors: Roles in viral entry, tropism, and disease, Annu Rev Immunol, 17, pp. 657-700, (1999)
[3] Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R., Homozygous defect in HIV-I coreceptor accounts for resistance of some multiply exposed individuals to HIV-I infection, Cell, 86, pp. 367-377, (1996)
[4] Goila R., Banerjea A.C., Sequence specific cleavage of HIV-1 coreceptor-CCR5 gene by a hammer-head ribozyme and a DNA-enzymes. Inhibition of the coreceptor function by DNA-enzymes, FEBS Lett, 436, pp. 233-238, (1998)
[5] Bai J., Rossi J., Akkina R., Multivalent anti-CCR5 ribozymes for stem cell-based HIV type I gene therapy, AIDS Res Hum Retroviruses, 17, pp. 385-399, (2001)
[6] Bai J., Gorantla S., Banda N., Cagnon L., Rossi J., Akkina R., Characterization of anti-CCR5 ribozyme transduced CD34+ hematopoetic progenitor cells in vitro and in a SCID-hu mouse model in vivo, Mol Ther, 1, pp. 244-254, (2000)
[7] Qin X.F., An D.S., Chen I.S., Baltimore D., Inhibiting HIV-I infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5, Proc Natl Acad Sci USA, 100, pp. 183-188, (2003)
[8] Anderson J., Banerjea A., Akkina R., Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-I resistance, Oligonucleotides, 13, pp. 303-312, (2003)
[9] Lisziewicz J., Sun D., Smythe J., Lusso P., Lori F., Louie A., Markham P., Rossi J., Reitz M., Gallo R.C., Inhibition of human immunodeficiency virus type I by regulated expression of polymeric TAT activation response RNA decoy as a strategy for gene therapy for AIDS, Proc Natl Acad Sci USA, 90, pp. 8000-8004, (1993)
[10] Michienzi A., Li S., Zaia J.A., Rossi J.J., A Nucleolar TAR decoy inhibitor of HIV-I replication, Proc Natl Acad Sci USA, 99, pp. 14047-14052, (2002)

← 1 2 3 →